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Abstract  
To determine the prevalence, sociodemographic and characteristics of patients with 
pre-eclampsia attending HUSM and subsequently determine the maternal and 
perinatal outcomes. 
of these patients.  
Methodology: Descriptive study, retrospective data collection for 10 years duration 
from 2006-2016. 
Material and method: 283 cases were selected randomly and all important data such 
patients age, parity, BMI, medical background, gestation, clinical complaints, 
relevant laboratory results, mode of delivery, maternal and fetal complications were 
recorded and analysed.  
Results: The prevalence of pre-eclampsia in HUSM for that period of study was 1.4 
percent. Mean age of the patients were 30.39 years. Majority (98.2%) of patients 
with pre-eclampsia had antenatal booking, 59% were multigravida, while 41% were 
primigravida . Our patients had a mean BMI of 30 kg/m2 and a mean haemoglobin  
of 10.2 g/dl . 64.7% has a raised serum uric acid level, 94% had a raised ALT level 
and 53% had a raised AST level. 23% of patients suffered from complications, with 
the most common being PPH (9.5%).  A platelet level of <150 x109 was associated 
with a significant risk of maternal complications (95% CI 1.57, 6.52, p=0.001). Mean 
fetal weight was 2.53 kg, and 37% needed NICU admission. Patients with GDM had 
significantly higher odds of having low birth weight fetus (95% CI 2.38, 8.69, 
p<0.001) and more likely to be admitted to NICU (95% CI 0.99, 4.98, p=0.051).  
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Conclusion: The prevalence of pre-eclampsia in this study is much lower than those 
quoted in other studies, whist clinical characteristics were almost similar 
 
Key Words: Pre-eclampsia, Maternal outcomes, fetal outcomes, sociodemographic 
characteristics.  
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Abstrak  
	
Objektif adalah untuk menganalisis kelaziman, data sosiodemografi, ciri-ciri pesakit 
serta kesudahan ibu ibu serta kandungan pesakit pesakit pre-eklampsia yang datang 
ke HUSM 
 
Desain :Pengumpuan data secara retrospektif dan diskriptif selama 10 tahun dari 
2006 hingga 2016 
 
Metodologi : 283 pesakit telah dipilih secara rawak dan semua butir butir mengenai 
umur , jumlah anak, BMI, sejarah perubatan, jangkamasa kandungan, aduan klinikal, 
keputusan makmal, cara bersalin serta kesudahan ibu dan anak yang dikandung 
direkod dan dianalisa. 
 
Keputusan:  Pre-eklampsia di HUSM mempunyai kelaziman sebanyak 1.4 peratus. 
Purata umur pesakit pre-eklampsia adalah 30.3 tahun. Kebanyakkan (98.2%) pesakit 
pre-eklampsia mempunyai pemeriksaan prenatal, 59 peratus merupakan multigravida 
manakala 41% merupakan primigravida. Pesakit kami mempunyai purata BMI 30.56 
kg/m2 serta purata haemoglobin 10.2 g/dl. 64.7 % mempunyai urik asid yang tinggi, 
94% mempunyai ALT yang tinggi dan 53% mempunyai yang AST tinggi. Sebanyak 
23% pesakit mengalami komplikasi akibat pre-eklampsia. Komplikasi paling banyak 
adalah pendarahan akut (9.5%). Platlet < 150 x109 g/dl berkait dengan komplikasi 
dikalangan ibu ibu pre-eklampsia (95% CI 1.57, 6.52, p=0.001). Purata berat bayi i 
pula adalah 2.53.kgs dan 37% memerlukan kemasukkan ke NICU. Kebarangkalian 
pesakit  pre-eklampsia yang mempunyai GDM mempunyai bayi yang kurang berat  
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serta memerlukan kemasukan ke NICU adalah lebih tinggi berbanding berbanding 
dengan yang tiada. 
 
Konklusi : Kelaziman pre-eklampsia di HUSM adah 1.4 % , lebih rendah berbanding 
dengan kajian-kajian lain. Walaubagaimanapun  , ciri ciri klinikal pesakit hampir 
sama.	  
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1.0 Introduction 
	
Pre-eclampsia is a disorder that was first described in ancient Greek 
scriptures, obtaining its name from the ‘Greek’ word “eclampsis’ which means 
sudden flashing. Prior to the 18th century, the term eclampsia was used to refer to the 
visual phenomenon experienced by the mother which accompanied the actual 
neurological phenomena. It was not until the 18th century would experts coin the 
term ‘pre-eclampsia’ to describe a disorder that would actually pre-empt the 
neurological sequalae, and make the association between hypertension and 
proteinuria. 
Being a disorder unique to pregnancy and the postpartum period, pre-
eclampsia is a disorder that affects both the mother and the unborn. Complicating at 
least 5-10 percent of pregnancies [1] world-wide, it is a rapidly progressing disorder 
and could lead to detrimental effects on the mother and fetus. With more affluent 
socio-economic status and increasing sedentary lifestyle, limited data has suggested 
an upward trend of pre-eclampsia, essentially in rapidly developing countries like 
Malaysia. 
Despite tremendous improvements in healthcare in the recent millennia, 
reports of pregnant women dying from pre-eclampsia still exists. As per Noraihan et. 
al. [2] in Maternity Hospital Kuala Lumpur (MHKL), the prevalence of hypertensive 
disorder in pregnancy was 82.3 per 1000 deliveries and was one of the leading 
causes of maternal mortality from 1984 to 2000. This was a tremendous 
improvement as compared to the early 1960s where the occurrence of eclampsia was 
reported to be 450 per 10 000 births in MHKL [2]. With the improvement and 
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increased uptake of maternal child health services, the prevalence has dropped to 14–
30 per 10 000 deliveries in 1993 to mid 1999. 
Locally in Kelantan, the incidence of hypertensive diseases complicating 
pregnancy in the state was 3.8 per cent in 2012 [3]. The presence of medical retrieval 
teams in the state and adequate resuscitation training has contributed to considerable 
improvement in the management of the eclamptic mother.  
1.2 Literature review 
1.2.1 Hypertensive disorders of pregnancy 
	
Defining what represents hypertension in pregnancy is complicated by the fact 
that blood pressure levels in pregnancy are even more dynamic than they are in non-
pregnant women. There are various classifications for Hypertension in Pregnancy. 
1.2.2 Classification of Hypertensive disorders of Pregnancy 
	
The Australasian Society for the Study of Hypertension in Pregnancy 
(ASSHP) 2008 and endorsed by the International Society for the Study of 
Hypertension in Pregnancy (ISSHP)  defines hypertension as a sustained  blood 
pressure of ≥ 140/90 at least four hours apart [4]. 
1. As follows are the types of Hypertensive diseases in pregnancy :Pre-
eclampsia-eclampsia: clinically diagnosed in the presence of de novo 
hypertension after 20 weeks of gestation, and one or more of the following:  
i. Significant proteinuria. ( Albumin 2+ or more , or 24 hour urine 
protein of 0.3mg/24hours 
ii. Renal insufficiency 
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iii. Liver disease: raised transaminases  
iv. Neurological problems: convulsions (eclampsia), hyperreflexia with 
clonus or severe headaches, persistent visual disturbances (scotoma).  
v. Haematological disturbances: thrombocytopenia, coagulopathy, 
haemolysis.  
vi. Fetal growth restriction. 
2. Gestational hypertension is a clinical diagnosis defined by the new onset of 
hypertension in the absence of proteinuria or new signs of end-organ 
dysfunction.  
 
3. Chronic hypertension is hypertension diagnosed prior to 20 weeks of 
gestation or presence of hypertension preconception, or de novo hypertension 
in late gestation that fails to re-solve postpartum. It is essential hypertension 
if there is no underlying cause and secondary hypertension if there is 
underlying cause such as renal, cardiac or endocrine disease. Chronic 
hypertension may present for the first time as gestational hypertension. 
4. Pre-eclampsia superimposed on chronic hypertension is diagnosed in the 
presence of any of the following, in a woman with chronic hypertension:  
a. De novo proteinuria after 20 week gestation  
b. A sudden increase in the severity of hypertension  
c. Appearance of features of pre-eclampsia-eclampsia, and  
	 A sudden increase in proteinuria in women who have pre-existing 
proteinuria early in gestation 
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1.3 PRE-ECLAMPSIA PATHOPHYSIOLOGY 
	
Research efforts this past decade have enable scientists and clinicians to 
come closer to aetiology and causality of pre-eclampsia thus improve diagnosis and 
even predict pre-eclampsia with the ultimate hope that this will lead to the ‘holy 
grail’ of subsequent prevention and tailored treatments for pre-eclampsia which was 
once called the ‘greatest riddles of obstetrics and gynaecology’ by Naquib Pasha 
Mahfouz – Father of modern obstetrics and gynaecology 
The pathophysiology of pre-eclampsia is indeed complex, and to date the 
exact cause is still unknown, but it likely to involve the maternal-fetal-placental 
complex. Relative under-perfusion due to abnormal development of the placenta 
vasculature early in the pregnancy results in the release of antiangiogenic factors into 
the maternal circulation that alter maternal systemic endothelial function and lead to 
hypertension and other manifestations of the disease. The exact trigger for these 
abnormal development and the trajectory of the  subsequent cascade of clinical 
events remains unknown and unpredictable. 
 
1.3.1 Abnormal placental development 
 
Defective spiral artery formation and trophoblast invasion leads to impaired 
placentation and placental hypo-perfusion and thus ischemia, which are thought to be 
the primary events leading to a state of systemic endothelial dysfunction, the 
pathologic precursor of pre-eclampsia. 
In normal pregnancies as early as 10 week,  the trophoblastic cells of the 
developing placenta migrate and invade both the endothelium and tunica media of 
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the maternal spiral arteries. As a result, these vessels undergo reformation from small 
muscular arterioles to large capacitance vessels of low resistance, thus ensuring 
greater blood flow to the placenta and thus the fetus.  
However, in pre-eclampsia, the trophobastic cells migration infiltrate the 
decidual portion of the spiral arteries in a defective manner, and fail to invade 
through the myometrial segment. The spiral arteries thus do not develop into large 
tortuous pliable vessels for high volume, low resistance blood supply to the 
developing placenta and thus the fetus. Instead the vessels remain small and rigid , 
resulting in placental ischemia.  This defective placentation has been associated with 
the development of pre-eclampsia.  
1.3.2 Immunological factors 
	
There is circumstantial evidence that pre-eclampsia is immune mediated, and 
this comes from in part the observation that prior exposure to paternal antigens 
appear to protect the mother against pre-eclampsia.  According to Duckitt et al [5],  
reduced exposure to paternal antigen in nulliparous women, women with long inter-
pregnancy interval, women who use barrier contraception or women who conceive 
via artificial reproductive methods are at increased risk of pre-eclampsia. 
Immunologic abnormalities, similar to those observed in organ rejection graft 
versus host disease, have also been observed in pre-eclamptic women as per Gleicher 
et al [6]. The extravillous trophoblast (EVT) cells express an unusual combination of 
HLA class I antigens: HLA-C, HLA-E, and HLA-G. Natural killer (NK) cells that 
express a variety of receptors known to recognize class I molecules infiltrate the 
maternal decidua in close contact with the EVT cells [6]. Interaction between NK 
cells and EVT cells has been hypothesized to control placental implantation. In pre-
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eclampsia, conflict between maternal and paternal genes is believed to induce 
abnormal placental implantation through increased NK cell activity 
1.3.3 Genetic factors 
	
 Despite being generally a sporadic disease, genetic factors may have a role in 
susceptibility to pre-eclampsia. Cincotta et al [7] found that primigravida women 
with a family history of pre-eclampsia (eg, affected mother or sister) have a two- to 
five-fold higher risk of the disease than primigravid women with no such history. 
Studies of sisters, daughters, grand daughters and daughter in laws of eclamptic 
women and concluded have that pre-eclampsia/eclampsia was highly heritable.. The 
risk of pre-eclampsia is increased more than seven-fold in women who have had pre-
eclampsia in a previous pregnancy. 
 
	
	
 
1.4: MATERNAL OUTCOMES  
 
Women with pre-eclampsia are at increased risk for abruptio placentae, acute 
renal failure, cerebral haemorrhage, disseminated intra-vascular coagulation, 
pulmonary oedema, circulatory collapse and oedema.  
Despite having a small sample size, Stirrat et al. [8]  in a retrospective cohort 
study of on 71 pre-eclamptic women with gestational age less than 30 weeks,  found 
that 21% had developed HELLP syndrome, 15%  had abruptio placenta, 13%  had 
renal failure and 1.4%  eclampsia.   
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In a much larger study , Al-Mulhim et al. [9] on the other hand reported that 
the commonest complication to be abruptio placenta (1.6%) followed by oliguria 
(7.9%), coagulopathy (6%) and renal failure (4.1%) .  This is in contrast to what that 
has been reported in the Malaysian National Obstetrics Registry whereby eclampsia 
was the commonest complication at 3.26% in 2011 and 3.24% in 2012 respectively, 
followed by postpartum haemorrhage at 1.40% in 2011 and 0.83 % in 2012,   while 
the incidence of abruptio placenta in 2012 was 1.08% [10].  
According to Cuningham et. al. [11] despite these presentations, many 
women have no symptoms. Most patients are usually nulliparous and present with 
new-onset hypertension and proteinuria at ≥34 weeks of gestation. Approximately 10 
percent of affected women develop these signs and symptoms at <34 weeks of 
gestation and rarely as early as 20 to 22 weeks. In approximately five percent, the 
signs and symptoms are first recognized postpartum (ie, postpartum pre--eclampsia), 
usually within 48 hours of delivery. 
1.5 NEONATAL OUTCOME 
	
Pre-eclampsia accounts for more than 40% of premature deliveries  and 
substantially increases the risk of low birth weight, and SGA births. Ananth et al. 
[12]  in their study found eclampsia to have substantially greater risk of delivery of 
very low birth weight infants (birth weight < 1,499 gm) and moderate low birth 
weight infants (1,500-2,499 gm) and very pre-term (Gestational age < 33 weeks ) 
and moderately pre-term (33-36 gestational age) birth compared with women without 
hypertension . 
A retrospective cohort study performed by Xiong et al. [13] gestation was 0.6 
weeks shorter in women with severe pre-eclampsia than in normotensive women 
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(P<0.01). After adjustment for duration of gestation and other confounders their 
study showed that pre-eclampsia and severe pre-eclampsia increased the risks of 
intra uterine growth restriction(IUGR) and low birth weight. Babies born to mothers 
with pre-eclampsia are also more likely to be admitted to the NICU as compared to 
those who did not. 
Magee et al. [14]  in a multi-centre retrospective cohort study, found that 
16.4% of pre-eclamptic pregnancies being complicated by low birth weight and 
34.3% by pre-term birth, regardless of hypertension type. 
1.6 Risk Factors for developing pre-eclampsia 
	
Family history of hypertension, extremes of reproductive age, primigravidity, 
diabetes, renal disease,  and hypertension prior to pregnancy are some of the 
predisposing factors of preeclampsia . According to Duckitt et. al. [5], women aged 
40 and above are more likely to suffer from pre-eclampsia as compared to their 
younger counterparts. However at the sametime, women of older age are also more 
likely to suffer from other comorbidities that could contribute to the risk of pre-
eclampsia. 
Inter pregnancy interval less than six months and longer than 59 months are 
associated with an increased risk of adverse maternal outcome . Conde-Agudelo et 
al. [15]  in their study found that, compared with women with inter-pregnancy 
interval of 18 to 23 months, women with inter-pregnancy intervals longer than 59 
months had significantly increased risk of pre-eclampsia and eclampsia. 
Obesity is risk for developing pre-eclampsia as per Duckiit et al [5]. The exact 
mechanism by which obesity is associated with an increased risk of pre-eclampsia is 
	
	
13	
	
not completely understood. It has been hypothesized that the increased oxidative 
stress due to the hyper-dynamic circulation associated with obesity and 
dyslipidaemia lead to pre-eclampsia .  
1.7  Diagnostic tests  
	
As there is no widely available, cheap investigative test for diagnosis of pre-
eclampsia -the initial diagnosis of pre-eclampsia remains still remains clinical and 
the classification of severity is mainly based on the blood pressure values and both 
clinical and biochemical assessments. Measuring blood pressure is cumbersome in 
clinical setting  but if raised blood pressure and proteinuria are observed at the 
antenatal care setting the woman should be referred for further evaluation. 
 
	
1.7.1 Uric acid 
	
Serum uric acid is used as an indicator of disease severity in established pre-
eclampsia and has been reported to be better predictor for adverse perinatal outcome 
than blood pressure .  
In a study conducted by Williams KP et al [16] found  a significant elevation 
in serum uric acid levels over normotensive pregnant women in both women with 
gestational hypertension   and the preeclamptic women. In this study  and other 
similar studies however, serum uric acid levels although significantly elevated in 
women with gestational hypertension and pre-eclampsia, were not prognostic 
indicators of severity of the maternal and fetal outcome .  
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1.7.2 Proteinuria 
	
Proteinuria presence of proteinuria in a pregnancy patient after 20 weeks of 
gestation with hypertension should alert the clinician on a diagnosis of pre-
eclampsia. Dipstick proteinuria is the most common screening test for pre-eclampsia. 
It is easy and cheap to use. The purpose of using dipsticks is to assist in timely 
diagnosis of pre-eclampsia. Other methods of diagnosis include 24 hour urine protein 
levels and spot creatinine/protein ratio.  
1.7.3 Platelet Count 
 
As a pregnancy progresses, its physiological for the platelet levels to drop as 
well due to normal maternal blood volume expansion. In pre-eclampsia however, 
there is a more marked drop in maternal platelet levels, due to increased consumption 
and intravascular destruction. Microscopic endothelial injury that accompanies pre-
eclampsia results in platelet consumption from the formation of fibrin microthrombi 
in the circulation [17]. In sync with immune mediated factors, this further potentiates 
the degree of thrombocytopenia in pre-eclampsic mothers. 
1.7.4  Liver Enzymes 
	
According to Dekker et al [18], elevation of serum Alanine Amino Transferase 
(ALT) and Aspartate Amino Transferase(AST) can be used as surrogate marker of 
severity of pre-eclampsia; they increase in pre-eclampsia as a result of leakage across 
the cell membrane . 
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1.8 MANAGEMENT OF PRE-ECLAMPSIA 
	
Even though delivery is the ultimate cure for pre-eclampsia, management aimed 
at benefiting the mother may be detrimental to the fetus because premature birth is a 
significant cause of infant morbidity and mortality. Hence the management of pre-
eclampsia is usually based on a step-wise protocol: Pregnant women should be 
screened; those at risk should be monitored once a diagnosis is made; the maternal 
condition should be stabilized; monitoring should be continued and delivery should 
be initiated at the best time for the mother and the baby . During labour, the 
management goals are to prevent seizures and control hypertension. 
The predominant mode for controlling pre-eclampsia includes anti-
hypertensive, anti-convulsions and delivery . Severe pre-eclampsia and eclampsia, 
are life threatening, therefore women suspected of having either condition should 
receive immediate and continuous care by trained health care personal 
The primary objective of treatment in women with pre-eclampsia is to 
prevent cerebral complications such as encephalopathy and haemorrhage. . In a 
Cochrane review of 11 trials (1,128 women), Magee and Duley [19] observed that 
beta-blockers reduce the risk of severe pre-eclampsia. However, until better evidence 
is available, the choice of anti-hypertensive should depend on the experience and 
familiarity of an individual clinician with a particular drug and on what is known 
about the adverse maternal and fetal side effects . 
 The Magpie trial, a large multi-centred double blinded randomised trial 
carried out in 33 countries and involving nearly 10,000 pregnant women with pre-
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eclampsia settled the issue for magnesium sulphate [20]. From that study it was 
found that women allocated magnesium sulphate had a 58% lower risk of having 
eclampsia as compared to placebo. 
Maternal mortality was also lower among women allocated magnesium 
sulphate. Side effects were only minor: neither the mothers nor their babies showed 
any serious adverse effects from treatment . This trial showed that giving magnesium 
sulphate injections could save countless lives across the world if it would be given 
routinely to pregnant women with pre-eclampsia. Importantly, it is an inexpensive 
treatment, making it especially suitable for use in low-income countries . 
 
1.9 Rational of Study  
	
Despite the high prevalence, there is not much published data on the 
characteristics of these patients in Malaysia. Therefore the aim of this study is to 
determine the maternal and fetal outcome and associated factors in preeclamptic 
patients treated in a tertiary referral hospital. The results from this study will also 
throw some light on the predisposing circumstances of pre-eclampsia and 
characteristics of patients with pre-eclampsia . Recommendations can be made 
depending on the findings. This can help determine the future direction of the 
prevention and management of this dangerous condition, as it is still a significant 
problem in Malaysia. 
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A retrospective study on Pre- eclampsia in Hospital University Sains Malaysia , 
Kelantan 
Introduction 
Hypertensive disorders complicate 5–10% of pregnancies worldwide, with limited 
data suggesting an upward trend in incidence most likely related to increasing 
maternal weight and sedentary lifestyle. With few differences, all international 
societies define the hypertensive disorders of pregnancy as chronic hypertension, 
gestational hypertension and pre-eclampsia1. Although women with pre-eclampsia 
have the greatest risk of maternal and perinatal complications, what constitutes pre-
eclampsia is controversial, and diagnostic distinctions are often blurred2. As such, it 
is important to view all women with a hypertensive disorder of pregnancy and their 
babies as being at increased risk of mortality and morbidity, and act accordingly. 
Pre-eclampsia remains one of the top five causes of maternal and perinatal mortality 
worldwide. Our best estimate is that pre-eclampsia claims the lives of more than 
70,000 women per year and more than 500,000 of their fetuses and newborns; this is 
equivalent to the loss of 1600 lives per day. For every woman who dies, it is 
estimated that another 20 suffer a life-altering morbidity4.  
Given that maternal (and perinatal) deaths and sequelae result primarily from delays 
in triage, transport, identification and treatment, it would seem important for the 
global community to turn its attention to community-based care. A community-
focused approach could include community engagement and use of innovative 
technologies, like smartphone applications could be used to support community-
based health workers.  
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In addition, however, care at facility must be of high quality in order for outcomes to 
be improved, a point that has been highlighted by the move towards encouraging 
more facility births and concerns about the quality of care received there. In the 
World Health Organization Multicountry Survey on Maternal and Newborn Health 
(WHOMCS) that covered 357 health facilities in 29 countries, high coverage of 
essential interventions was not associated with reduced maternal mortality. As such, 
attention must also be focused on strengthening provision of evidence-based 
comprehensive emergency obstetric care, conducting maternal death and near-miss 
morbidity surveillance and response, and performing large-scale effectiveness 
evaluations . 
In Malaysia, from 1997-2008 the average incidence of HDP related maternal death 
was 13.6%. It is the 4th leading cause of maternal mortality in Malaysia 5 . In 
Maternity Hospital Kuala Lumpur (MHKL), hypertensive disorder is common, with 
a prevalence of 82.3/1000 deliveries and was one of the leading causes of maternal 
mortality from 1984 to 2000 , tremendous improvement as compared to the early 
1960s where the occurrence of eclampsia was reported to be 450 per 10 000 births in 
MHKL 3.  With the improvement and increased uptake of maternal child health 
services, the prevalence has dropped to 14–30 per 10 000 deliveries in 1993 to mid 
1999 3.  
Locally in Kelantan, the incidence of hypertensive diseases complicating pregnancy 
in the hospital population was 8.3 per cent (1988). Three of the 23 maternal deaths in 
1988 was due to eclampsia. During that study, it was noted that the death rate in 
eclampsia of 4.8 per cent resulted from a combination of several factors that show 
wide variability. Delay in referral because of socio-cultural reasons was a problem 6. 
The absence of medical retrieval teams in the state and inadequate resuscitation 
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while in transit contributed to considerable deterioration in the haemodynamic state 
of the eclamptic mother. This condition however has improved tremendously with 
the improvement of the Malaysian Health Services 6. 
 
Rationale and Justification of the Study 
Despite the high prevalence, there is not much published data on the outcome of 
these patients in Malaysia. Therefore the aim of this study is to analyze the maternal 
and fetal outcome and associated factors in pre-eclamptic patients treated in a tertiary 
referral hospital. The results from this study will also throw some light on the 
predisposing circumstances of pre-eclampsia and characteristics of patients with pre-
eclampsia . Recommendations can be made depending on the findings. This can help 
determine the future direction of the prevention and management of this dangerous 
condition, as it is still a significant problem in Malaysia. 
Literature review 
For the purpose of this study, the definition below are used for this study 7 
There are various classifications for Hypertension in Pregnancy. The most recent is 
by the Australasian Society for the Study of Hypertension in Pregnancy (ASSHP) 
and endorsed by the International Society for the Study of Hypertension in 
Pregnancy (ISSHP)  
1. Pre-eclampsia-eclampsia: clinically diagnosed in the presence of de novo 
hypertension after gestational week 20, and one or more of the following:  
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i. Signicant proteinuria. ( Albumin 2+ or more , or 24 hour urine 
protein of 0.3mg/24hours 
ii. Renal insuffciency: serum creatinine ≥ 90 micromol/l or oliguria.  
iii. Liver disease: raised transaminases  
iv. Neurological problems: convulsions (eclampsia), hyperexia with 
clonus or severe headaches, persistent visual disturbances (scotoma). 
 
v. Haematological disturbances: thrombocytopenia, coagulopathy, 
haemolysis.  
vi. Fetal growth restriction.  
 
Gestational hypertension is hypertension detected for the first time after 20 weeks 
pregnancy. The definition is changed to “transient” when pressure normalizes 
postpartum.  
2. Chronic hypertension is hypertension diagnosed prior to gestational week 20 
or presence of hypertension preconception, or de novo hypertension in late 
gestation that fails to resolve postpartum.  
3. Pre-eclampsia superimposed on chronic hypertension is diagnosed in the 
presence of any of the following, in a woman with chronic hypertension:  
i. De novo proteinuria after 20 week gestation  
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ii. A sudden increase in the severity of hypertension  
iii. Appearance of features of pre-eclampsia-eclampsia, and  
iv. A sudden increase in proteinuria in women who have pre-existing 
proteinuria early in gestation  
 
 
PRE-ECLAMPSIA: INCIDENCE, CONSEQUENCES AND RISK FACTORS 
Pre-eclampsia complicates 2-8% of pregnancies 8. Women with pre-eclampsia are at 
increased risk for abruptio placentae, acute renal failure, cerebral haemorrhage, 
disseminated intravascular coagulation, pulmonary oedema, circulatory collapse and 
oedema. In a retrospective cohort study of Murphy and Stirrat 9 on 71 pre-
eclampticwomen with gestational age less than 30 weeks  21% had developed 
HELLP syndrome, 15%  had abruptio placenta, 13%  had renal failure and 1.4%  
eclampsia but maternal mortality was not observed.  Al-Mulhim et al. also reported 
that the commonest complication to be abruptio placenta (12.6%) followed by 
oliguria (7.9%), coagulopathy (6%) and renal failure (4.1%) 10. 
Risk Factors 
Family history of hypertension, extremes of reproductive age, primi-gravidity, 
diabetes, renal disease, hypertension prior to pregnancy, and black race are some of 
the predisposing factor of pre-eclampsia  11,12,13. Women 40 years and above are 
more  than five times likely to die of pre-eclampsia than those between 20 and 24 
years older. Some studies reflected that neither maternal age nor race had a 
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significant effect on the outcome of pre-eclampsia, but suggested that increased 
severity of disease might be an important determining factor 14,15. 
In a cohort study of 878,680 pregnancies in 700 hospitals in Latin America and 
Caribbean, the following risks factors were significantly associated with increased 
risks of pre-eclampsia: Nulliparity (RR = 6.6, 95% CI 5.6-9.8), multiple pregnancy 
(RR= 2.0;95%CI 0.9-6.4), history of chronic hypertension (RR=3.9; 95%CI 3.8 – 
4.4), gestational diabetes mellitus (RR=3.9; 95% CI 4.6 – 6.6), maternal age > 35 
years (RR=6.7; 95%CI 5.8 -7.7) and a mother not living with infant’s father 
(RR=2.1; 95% CI 1.5 -2.6). The pattern of risk factors among nulliparous and 
multiparous in this study was quite similar 
8 16. Type 1 diabetes (OR =5.58; 95%CI 2.72 - 11.43) and twin births (OR= 3.11, 
95%CI 1.61 - 6.00) were also significantly associated with pre-eclampsia according 
to a study conducted by Ros et al. 17. 
Pre-eclampsia occurs mainly in first pregnancies, suggesting that previous exposure 
to paternal antigen is protective 18. Indeed a previous normal pregnancy is associated 
with lowered frequency of pre-eclampsia and the protective effect of multiparty is 
lost with change of partner 18. The idea that paternal antigen is protective is 
supported by the increased risk of pre-eclampsia in those who carry a pregnancy by a 
new father. Data based on Norwegian population (1967-1992) confirmed the impact 
of paternal factor on the risk of developing pre-eclampsia. Men who fathered pre-
eclamptic pregnancies were twice as likely to father a pre-eclamptic pregnancy from 
different women regardless of whether she had a prior pre-eclamptic pregnancy or 
not 18. The protective effect of along-term sperm exposure might also provide 
explanation for the high frequency of pre-eclampsia in teenage pregnancy 18. 
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Another study of Trogstad et al. showed that a change of paternity for the second 
pregnancy was associated with a reduced risk of pre-eclampsia after controlling for 
the time since first delivery (AOR = 0.80, 95%CI: 0.72-.90), but the interaction 
between change in paternity and time between deliveries was significant only for 
women with no previous pre-eclampsia. This implies that the increase in pre-
eclampsia risk ascribed to a new father may be due to insufficient control for inter-
pregnancy interval 19. Inter pregnancy interval less than six months and longer than 
59 months are associated with an 
increased risk of adverse maternal outcome 20. Conde-Agudelo and Belizan  in their 
study found that, compared with women with inter-pregnancy interval of 18 to 23 
months, women with inter-pregnancy intervals longer than 59 months had 
significantly increased risk of pre-eclampsia (OR=1.83; 95% CI 1.72-1.94) and 
eclampsia (OR= 1.80; 95% CI 1.38-2.32). 
 
Therefore health care providers should realize that the antenatal care of a multiparous 
patient with a new partner should be the same as in a woman presenting with her first 
pregnancy as far as the risk of pre-eclampsia is concerned and inter-pregnancy 
history needs to be taken into consideration. 
Obesity is also a definite risk for developing pre-eclampsia. The exact mechanism by 
which obesity is associated with an increased risk of pre-eclampsia is not completely 
understood. Possible explanations include increased stress due to the hyper-dynamic 
circulation associated with obesity and dylipidemia or increased oxidative stress 18. 
DIAGNOSIS 
